Researchers from Yale School of Medicine, along with Helsinki University Hospital and University of Helsinki, have reported data from a study that aimed to assess the effects of a common variant in hydroxysteroid 17-β dehydrogenase 13 (HSD17B13 rs72613567-A) in the liver.
Two papers in the Feb. 8, 2023, issue of Cell Host & Microbe have reported new insights into the relationship between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and alterations in the gut microbiome, and how those relationships change over time. A reliable way to diagnose ME/CFS would be a huge step forward for the study of ME/CFS. Currently, the condition is diagnosed purely by symptoms, which are assessed via questionnaire.
Insulin resistance in type 2 diabetes (T2DM) is associated with hepatosteatosis and the development of nonalcoholic fatty liver disease (NAFLD), with the pathogenesis of NAFLD being complex and involving the crosstalk between the liver and white adipose tissue (WAT).
Rise Therapeutics LLC has received FDA clearance for its IND application to proceed with a phase I trial of R-3750, a synthetic biology-based cellular immunotherapy being developed for the treatment of inflammatory bowel disease. The phase I trial will enroll patients with mild to moderate ulcerative.
Hepatocellular death is an important process for liver homoeostasis by elimination and replacement of impaired hepatocytes. Hepatocellular death occurs little under normal conditions in the healthy liver, and it plays a key role as a trigger of liver regeneration; meanwhile, hepatic steatosis increases hepatocellular death during liver regeneration, exacerbating both acute and chronic liver damage.
Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. have divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders.
Exegi Pharma LLC has received FDA clearance of its IND application for EXE-346, allowing the company to initiate a clinical trial to evaluate EXE-346 in the management of excessive stool frequency in patients with an ileal pouch-anal anastomosis (IPAA, J-Pouch).
Researchers from University Medical Center Utrecht and Yale University School of Medicine have recently described two novel, strictly anaerobic Allobaculum strains, 128T and 539T, isolated from the feces of humans with inflammatory bowel disease (IBD).
Shanghai Leadopharma Technology Co. Ltd. has presented transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists reported to be useful for the treatment of irritable bowel syndrome, Crohn's disease, ulcerative colitis, pain and inflammation.
RSS
